TP53 and neoplasm: In this context, data analysis from the TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy (Rx); NCT01888601) [167], discovered that certain somatic alterations, like MDM2 amplification in ADC and TP53 mutations in the ADC and SCC subtypes, were practically always truncal, sustained during tumor evolution, occurring prior to metastatic divergence, and were connected with an amplified tendency of metastasis.